October 12, 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Media
October 12, 2020
With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA
October 12, 2020
Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
October 09, 2020
Spruce Biosciences Announces Pricing of Upsized Initial Public Offering
October 08, 2020
Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models
October 07, 2020
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
October 01, 2020
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
October 01, 2020
Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
September 30, 2020
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
September 29, 2020
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
